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ABSTRACT	  	  
Disruption	  of	  the	  homeostatic	  balance	  of	  intestinal	  dendritic	  cells	  (DCs)	  and	  macrophages	  (MQs)	  may	  
contribute	  to	  inflammatory	  bowel	  disease.	  We	  characterized	  DC	  and	  MQ	  populations,	  including	  their	  
ability	  to	  produce	  retinoic	  acid,	  in	  clinical	  material	  encompassing	  Crohn’s	  ileitis,	  Crohn’s	  colitis	  and	  
ulcerative	  colitis	  (UC)	  as	  well	  as	  mesenteric	  lymph	  nodes	  (MLNs)	  draining	  these	  sites.	  Increased	  
CD14+DRint	  MQs	  characterized	  inflamed	  intestinal	  mucosa	  while	  total	  CD141+	  or	  CD1c+	  DCs	  numbers	  
were	  unchanged.	  However,	  CD103+	  DCs,	  including	  CD141+CD103+	  and	  CD1c+CD103+	  DCs,	  were	  
reduced	  in	  inflamed	  intestine.	  In	  MLNs,	  two	  CD14-­‐	  DC	  populations	  were	  identified:	  CD11cintHLADRhi	  
and	  CD11chiHLADRint	  cells.	  A	  marked	  increase	  of	  CD11chiHLADRint	  DC,	  particularly	  DRintCD1c+	  DCs,	  
characterized	  MLNs	  draining	  inflamed	  intestine.	  The	  fraction	  of	  DC	  and	  MQ	  populations	  expressing	  
aldehyde	  dehydrogenase	  (ALDH)	  activity,	  reflecting	  retinoic	  acid	  synthesis,	  in	  UC	  colon,	  both	  in	  active	  
disease	  and	  remission,	  were	  reduced	  compared	  to	  controls	  and	  inflamed	  Crohn’s	  colon.	  In	  contrast,	  
no	  difference	  in	  the	  frequency	  of	  ALDH+	  cells	  among	  blood	  precursors	  was	  detected	  between	  UC	  
patients	  in	  remission	  and	  non-­‐inflamed	  controls.	  This	  suggests	  that	  ALDH	  activity	  in	  myeloid	  cells	  in	  
the	  colon	  of	  UC	  patients,	  regardless	  of	  whether	  the	  disease	  is	  active	  or	  in	  remission,	  is	  influenced	  by	  
the	  intestinal	  environment.	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INTRODUCTION	  
Disruption	  of	   the	  homeostatic	  balance	   in	  the	   intestine	  of	  genetically	  susceptible	   individuals	  
can	  culminate	  in	  inflammatory	  bowel	  disease	  (IBD),	  such	  as	  Crohn’s	  disease	  (CD)	  or	  ulcerative	  colitis	  
(UC),	  where	   inappropriate	   reactivity	   to	  commensal	  bacteria	   that	  breach	   the	   intestinal	  barrier	  drive	  
inflammation.	   Studies	   performed	   largely	   in	   mice	   have	   shown	   that	   intestinal	   phagocytes,	   such	   as	  
dendritic	  cells	  (DCs)	  and	  macrophages	  (MQs),	  are	  central	  to	  maintaining	  homeostasis.	   In	  the	  steady	  
state	  these	  mononuclear	  phagocytes	  are	   less	   responsive	  to	   inflammatory	  signals	  and	  produce	  anti-­‐
inflammatory	  mediators	  that	  promote	  generation	  of	  regulatory	  T	  cells	  (Treg)	  1-­‐4.	  However,	  intestinal	  
inflammation	   alters	   the	   differentiation	   of	   monocyte-­‐derived	   cells	   and	   changes	   their	   function	   into	  
cells	  that	  promote	  inflammation	  3-­‐6.	  	  
Compared	   to	  mice,	   relatively	   little	   is	   known	   about	   human	  DCs	   and	  MQs	   in	   healthy	   versus	  
inflamed	  intestine.	  Intestinal	  MQs	  from	  healthy	  human	  intestine	  are	  hyporesponsive	  to	  inflammatory	  
stimuli	  2,	  7,	  8.	  In	  the	  inflamed	  human	  intestine,	  CD14+	  MQs	  accumulate	  and	  produce	  proinflammatory	  
cytokines	  3,	  9-­‐12.	  Accumulation	  of	  CD14+	  cells	  is	  also	  seen	  in	  mesenteric	  lymph	  nodes	  (MLNs)	  draining	  
inflamed	  intestine	  13.	  	  
Similar	   to	  MQs,	   DCs	   from	   healthy	   human	   lamina	   propria	   are	   hyporesponsive	   to	   some	   TLR	  
ligands	  14	  while	  those	  from	  inflamed	  intestine	  exhibit	  proinflammatory	  activity	  15,	  16.	  Consistent	  with	  
this,	  CD103+	  DCs	   from	  MLN	  draining	  healthy	   intestine	  promote	   induction	  of	   FoxP3+	  T	   cells	   17	  while	  
DCs	  from	  the	  MLN	  of	  active	  CD	  are	  proinflammatory	  and	  induce	  Th1	  T	  cells	  18.	  Indeed,	  healthy	  colon	  
epithelial	  cells	  seem	  to	  condition	  hyporesponsiveness	  in	  monocyte-­‐derived	  DCs	  and	  promote	  FoxP3+	  
T	  cells,	  a	  property	  that	  is	  reduced	  in	  epithelial	  cells	  from	  non-­‐inflamed	  CD	  patients	  17,	  19.	  
Studies	   of	   mouse	   intestinal	   DCs,	   using	   CD103	   and	   CD11b	   to	   define	   populations,	   have	  
identified	  distinct	  subsets	  with	  different	  origin	  and	   influence	  on	   intestinal	  homeostasis	  4,	   6,	   20-­‐23.	  The	  
human	  counterparts	  have	  been	  identified	  using	  CD103	  combined	  with	  other	  markers	  such	  as	  Sirpα	  or	  
CD141	  and	  CD1c	   21,	   23-­‐25.	  Mouse	  CD103+CD11b-­‐	   intestinal	  DCs	  are	  equivalent	   to	  CD103+Sirpα-­‐	   in	   the	  
human	  intestine,	  which	  are	  highly	  similar	  to	  CD141+	  DCs	  in	  human	  blood	  and	  other	  tissues	  24.	  Mouse	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CD103+CD11b+	   DC,	   which	   have	   a	   role	   in	   inducing	   mucosal	   Th17	   cells	   21,	   25,	   26,	   are	   related	   to	  
CD103+Sirpα+	  DCs	   in	  human	   intestine	  and	  CD1c+	  DCs	   in	  blood	  and	  skin.	  However,	   the	  role	  of	   these	  
recently	  identified	  human	  DC	  subsets	  in	  IBD	  is	  not	  known.	  
Retinoic	   acid	   (RA)	   is	   a	   vitamin	   A	  metabolite	   that	   has	  many	   immunomodulatory	   properties	  
depending	  on	   the	   context	   27,	   28.	   It	   is	   produced	   from	   retinol	   in	   a	   step-­‐wise	  process	   involving	   retinol	  
dehydrogenases	   and	   aldehyde	   dehydrogenases	   (ALDH).	   	   CD103+	   DCs	   in	   mouse	   intestinal	   tissue	  
produce	   RA,	   which	   allows	   these	   DCs	   to	   imprint	   intestinal	   homing	   properties	   to	   T	   and	   B	   cells	   and	  
promotes	   Treg	   development	   1,	   27.	   Similar	   to	   mice,	   human	   CD103+	   DC	   from	  MLN	   draining	   healthy	  
intestine	   imprint	   intestinal	   homing	   properties	   to	   T	   cells	   in	   a	   RA-­‐dependent	   fashion	   29	   and	   induce	  
FoxP3	  expression	  in	  T	  cells	  17.	  The	  ability	  of	  CD103+	  DCs	  from	  MLN	  to	  imprint	  intestinal	  homing	  on	  T	  
cells	  is	  similar	  in	  MLN	  draining	  healthy	  or	  inflamed	  ileum	  29.	  Despite	  these	  findings,	  which	  subsets	  of	  
mononuclear	   phagocytes	   in	   the	   human	   intestine	   have	   the	   ability	   to	  make	   RA	   and	  whether	   this	   is	  
localization	  dependent	  and	  regulated	  in	  context	  of	  intestinal	  inflammation	  is	  unknown.	  	  	  
The	  pivotal	  role	  of	  DC	  and	  MQs	  in	  intestinal	  homeostasis,	  and	  the	  unknown	  contribution	  of	  
recently	  identified	  human	  DC	  subsets	  in	  IBD,	  led	  us	  to	  dissect	  the	  population	  dynamics	  of	  MQ	  and	  DC	  
in	   inflamed	   and	   non-­‐inflamed	   intestinal	   tissue	   and	   MLN	   draining	   these	   sites.	   Extensive	   patient	  
cohorts	  were	  analyzed	  to	  compare	  ileum	  versus	  colon	  in	  CD	  and	  different	  colon	  segments	  in	  CD	  and	  
UC.	  We	   show	   that	  MQ	   and	  DC	   subsets	   follow	   a	   specific	   inflammatory	   pattern,	   both	   in	   the	   lamina	  
propria	   and	   MLN,	   which	   is	   similar	   at	   all	   locations	   and	   for	   both	   diseases.	   We	   also	   analyzed	   the	  
capacity	  of	  intestinal	  DC	  and	  MQ	  to	  produce	  RA.	  The	  data	  suggest	  that	  intestinal	  tissue	  of	  UC	  patients	  
influences	  ALDH	  production	  by	  myeloid	  cells,	  regardless	  of	  whether	  disease	  is	  active	  or	  in	  remission.	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RESULTS	  	  
Increased	  HLADRint	  macrophages	  characterize	  inflamed	  intestinal	  mucosa	  
To	  characterize	  MQs	   infiltrating	   the	   intestinal	  mucosa	  of	  patients	  with	  active	  CD	  or	  UC,	   lin-­‐
HLADR+CD14+	   cells	   were	   selected	   (Fig.	   1a	   and	   Suppl	   Fig.	   S1a).	   HLADR	   expression	   of	   these	   cells	  
differed	  in	  controls	  and	  inflamed	  patients	  so	  the	  cells	  were	  further	  divided	  into	  HLADRhi	  and	  HLADRint	  
populations	   (named	  DRhi	  MQs	  and	  DRint	  MQs,	   respectively)	   (Fig.	  1b).	  Both	  DRhi	  MQs	  and	  DRint	  MQs	  
from	   inflamed	   colon	   tissue	   showed	   higher	   expression	   of	   CD64,	   CD13	   and	   Sirpα	   as	   compared	   to	  
control	  tissue,	  while	  CD209	  expression	  was	  lower	  in	  DRint	  MQs	  at	  inflammation	  (Suppl	  Fig.	  1b).	  No,	  or	  
only	  moderate,	   differences	   in	   total	   DRhi	  MQ	   number	   (Fig.	   1c)	   or	   frequency	   (Suppl	   Fig.	   S1c)	   	   were	  
found	   at	   inflamed	   sites	   compared	   to	   non-­‐inflamed	   tissue	   for	   both	   ileum	   and	   colon.	   The	   same	  
occurred	  when	  comparing	  inflamed	  to	  non-­‐inflamed	  tissue	  taken	  from	  the	  same	  patient	  at	  the	  same	  
endoscopy	   (Fig.	  1D).	   In	  contrast,	   there	  was	  a	  sharp	   increase	   in	   the	  number	   (Fig.	  1e)	  and	   frequency	  
(Suppl	  Fig.	  S1d)	  of	  DRint	  MQs	  during	  inflammation,	  both	  compared	  to	  controls	  (Fig.	  1e	  and	  Suppl	  Fig.	  
S1d)	  and	  to	  non-­‐inflamed	  sites	  from	  the	  same	  patient	  (Fig.	  1F).	  Paired	  samples	  of	  inflamed	  and	  non-­‐
inflamed	  Crohn’s	  ileum	  could	  not	  be	  obtained	  due	  to	  ethical	  considerations.	  The	  number	  of	  DRhi	  MQs	  
and	  DRint	  MQs	  did	  not	  differ	  between	  controls	  from	  sigmoid	  and	  ascending	  colon	  (compare	  CD	  colon	  
control	  and	  UC	  colon	  control	   in	  Fig.	  1c	  and	  e).	  Likewise,	   the	  number	  of	  DRhi	  MQs	  and	  DRint	  MQs	   in	  
controls	   from	   ileum	   and	   ascending	   colon	   were	   similar	   (compare	   CD	   ileum	   control	   and	   CD	   colon	  
control	  in	  Fig.	  1c	  and	  e).	  	  
Increased	  DRint	  MQs	   in	   inflamed	   intestine	   suggests	   recruitment	   from	  the	  blood.	  To	  address	  
this,	   HLADR	   expression	   on	   CD14+	  monocytes	   from	   blood	   (Fig.	   2a)	  was	   compared	   to	   DRint	   and	  DRhi	  
MQs	   among	   LPMCs	   from	   colon	   tissue	   (Fig.	   1b)	   from	   the	   same	   patient.	   The	   median	   fluorescent	  
intensity	  (MFI)	  of	  HLADR	  was	  similar	  between	  CD14+	  monocytes	  and	  DRint	  MQs	  while	  DRhi	  MQs	  had	  
higher	  HLADR	  expression	  (Fig.	  2b).	  In	  summary,	  in	  Crohn’s	  and	  UC	  patients,	  recruitment	  of	  DRint	  MQs	  
increased	  in	  inflammation	  while	  DRhi	  MQs	  remained	  constant.	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CD141+CD103+	  and	  CD1c+CD103+	  DCs	  decrease	  in	  the	  inflamed	  intestinal	  mucosa	  
To	  further	  characterize	  antigen	  presenting	  cells	  in	  the	  mucosa	  of	  patients	  with	  active	  IBD,	  the	  
CD11c+	  fraction	  of	  lin-­‐HLADR+CD14-­‐	  cells	  was	  selected	  and	  henceforth	  called	  DCs	  (Fig.	  3a,	  left).	  Using	  
CD141	   and	  CD1c,	   two	   separate	   populations	   could	   be	  determined,	   both	   at	   steady	   state	  and	  during	  
inflammation	   (Fig.	   3a,	  middle	   and	   Suppl	   Fig.	   S2a).	   These	   cells	  were	   named	  CD141+	  DCs	   and	   CD1c+	  
DCs,	   respectively.	   No	   double	   positive	   CD141+CD1c+	   DCs	   were	   detected	   in	   either	   non-­‐inflamed	   or	  
inflamed	   tissue	   (Fig.	   3a	   and	  data	  not	   shown).	  During	   inflammation,	   no	   change	   in	   the	   frequency	  of	  
CD141+DCs	  or	  CD1c+DCs	  among	  LPMCs	  (Suppl	  Fig.	  S2b-­‐c),	  or	  in	  the	  frequency	  among	  DCs,	  (Suppl	  Fig.	  
S2d-­‐e)	  was	   found	   at	   any	   location,	   and	   numbers	   of	  DCs	   in	   the	   ileum,	   ascending	   colon	   and	   sigmoid	  
colon	  were	   similar	   (data	  not	   shown).	  CD141+	  DCs	  and	  CD1c+	  DCs	  were	   further	   analyzed	   for	  CD103	  
expression	   (Fig.	   3a,	   right).	   Reduced	   numbers	   of	   CD141+	   and	   CD1c+	   DCs	   expressing	   CD103	   were	  
detected	  during	   inflammation	   (Fig.	  3b,	  d).	  The	  same	  pattern	  was	  apparent	  when	  comparing	  paired	  
samples	  of	  inflamed	  and	  non-­‐inflamed	  tissue	  from	  the	  same	  patient	  at	  the	  same	  endoscopy	  (Fig.	  3c	  
and	   e).	   Again,	   no	   differences	   in	   numbers	   of	   CD103+	   DCs	   between	   intestinal	   locations	   could	   be	  
identified	  either	  at	  inflammation	  or	  steady	  state	  (compare	  cell	  numbers	  in	  Figure	  3b	  and	  d).	  Also,	  a	  
reduction	   in	   the	   frequency	   of	   CD103+	   cells	   among	   the	   CD141-­‐CD1c-­‐	   DCs	   was	   detected	   upon	  
inflammation	   (Suppl	   Fig.	   S3).	   Overall,	   the	   number	   and	   frequency	   of	   CD103+	   DCs	   among	   DCs	   was	  
decreased	   during	   inflammation	   (Supplementary	   Fig.	   S4).	   Thus,	   a	   reduction	   in	   CD103+	   DCs	  
characterizes	  intestinal	  lamina	  propria	  DCs	  during	  inflammation	  in	  CD	  and	  UC.	  	  
	  
DC	  composition	  in	  MLNs	  show	  distinct	  changes	  during	  inflammation	  	  
DCs	  migrate	  to	  lymph	  nodes	  to	  initiate	  T	  cell	  responses.	  We	  thus	  compared	  the	  composition	  
of	  DCs	   in	   the	  MLN	  of	   patients	  with	   inflammation	   relative	   to	   controls.	   	   In	   contrast	   to	   CD14-­‐CD11c+	  
lamina	   propria	   DCs,	   where	   a	   single	   population	   was	   apparent	   (Fig.	   3a),	  MLNs	   contain	   two	   distinct	  
populations	   of	   CD14-­‐CD11c+	   cells,	   one	   being	   HLADRhi	   and	   the	   other	   HLADRint	   (Fig.	   4a).	   These	  
populations	  were	   named	  DRhi	   DCs	   and	   DRint	   DCs,	   respectively.	   The	   ratio	   of	   these	   two	   populations	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revealed	   differences	   between	  MLNs	   from	   inflamed	   patients	   and	   controls,	  with	   DRhi	   DCs	   being	   the	  
main	  population	  at	  steady	  state	  while	  DRint	  DCs	  increased	  during	  inflammation	  (Fig.	  4b).	  	  
Obtaining	  MLNs	  draining	   the	   colon	  of	   control	   patients	   is	   highly	   limited	   for	   ethical	   reasons.	  
However,	  MLNs	  draining	  control	   ileum	  can	  be	  obtained	  in	  conjunction	  with	  bladder	  reconstruction.	  
Thus,	  MLNs	  draining	  inflamed	  colon	  or	  ileum	  were	  compared	  to	  control	  MLNs	  draining	  the	  ileum.	  The	  
DRhi/DRint	   DC	   ratio	   in	  MLNs	   draining	   inflamed	   colon	   from	   CD	   and	   UC	   patients	   was	   very	   similar	   to	  
MLNs	  draining	  inflamed	  CD	  ileum	  (Fig.	  4b).	  Also,	  no	  differences	  were	  detected	  regardless	  of	  whether	  
the	  MLNs	  drained	   ascending,	   descending	  or	   sigmoid	   colon	   (Fig.	   4b-­‐c;	   colors	   indicate	   samples	   from	  
the	   same	   patient).	   Thus,	   differences	   in	   the	   DRhi/DRint	   DC	   ratio	   in	   MLNs	   draining	   inflamed	   colon	  
compared	  to	   ileal-­‐draining	  control	  MLNs	  seemed	  not	   to	  depend	  on	   location	  per	  se,	  but	   rather	   that	  
the	  MLNs	  drained	   inflamed	   intestine.	  The	   shift	   from	  predominance	  of	  DRhi	  DCs	   in	   control	  MLNs	   to	  
DRint	  DCs	  in	  MLNs	  draining	  inflamed	  IBD	  intestine	  is	  shown	  schematically	  in	  Fig.	  4d-­‐e	  (compare	  total	  
blue	  to	  total	  red).	  	  
To	   determine	   which	   DC	   subsets	   accounted	   for	   the	   shift	   from	   DRhi	   to	   DRint	   DCs	   during	  
inflammation,	  MLN	  DCs	  were	  gated	  for	  CD141	  and	  CD1c.	  About	  half	  of	  the	  numerically	  abundant	  DRhi	  
DCs	  in	  control	  MLNs	  expressed	  CD1c	  (Figure	  4e,	  left).	  These	  were	  reduced	  upon	  inflammation	  while	  
DRint	   DCs,	   either	   expressing	   CD1c+	   DC	   or	   being	   CD141-­‐CD1c-­‐,	   increased	   in	  MLNs	   draining	   inflamed	  
tissue	   (Fig.	   4d-­‐e).	   Similar	   trends	  were	  detected	   in	   ileal	   and	   colonic	  CD	  as	  well	   as	  UC.	  This	   suggests	  
that	   inflammation	   resulted	   in	   similar	   relative	   changes	   in	   MLN	   DC	   subsets	   independent	   of	   the	  
intestinal	   compartment	  or	  disease.	   Since	  a	   shift	   from	  DRhi	   to	  DRint	  DCs	  was	  apparent	   in	  MLNs,	  but	  
control	  MLNs	   from	   the	   colon	  were	   not	   available	   to	   analyze	   for	   ethical	   reasons,	  we	   compared	   cell	  
populations	   in	   the	   intestinal	  mucosa	   to	  MLNs.	   As	   stated	   above,	   no	   difference	   in	   the	   frequency	   of	  
CD141+	   and	   CD1c+	   DCs	   in	   the	   intestinal	  mucosa	   could	   be	   detected	   between	   control	   and	   inflamed	  
tissue	  (Supplementary	  Fig.	  S2).	  We	  thus	  examined	  HLADR	  expression	  on	  mucosal	  DCs	  from	  patients	  
where	   inflamed	   and	   non-­‐inflamed	   intestinal	   tissues	   as	   well	   as	   MLNs	   were	   obtained.	   HLADR	  
expression	  on	  CD141+,	  CD1c+	  and	  CD141-­‐CD1c-­‐	  DCs	  was	  lower	  in	  inflamed	  compared	  to	  non-­‐inflamed	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tissue	  of	  the	  same	  patient	  with	  a	  similar	  pattern	  for	  colon	  and	  ileum	  (Figure	  4f).	  To	  further	  analyze	  
HLADR	  expression,	  blood	  and	  LPMC	  DCs	  (CD141+	  and	  CD1c+)	  from	  the	  same	  patient	  (UC	  patients	   in	  
remission)	   were	   analyzed	   and	   showed	   that	   DR	   expression	   increased	   in	   the	   tissue	   (Supplementary	  
figure	   S5).	   Thus,	   the	   shift	   from	  DRhi	   to	   DRint	   DCs	   seen	   in	   inflamed	  MLNs	   is	   consistent	  with	   HLADR	  
expression	   on	   LPMC	   DCs	   from	   inflamed	   tissue	   and	   HLADR	   is	   expressed	   at	   a	   higher	   level	   in	   tissue	  
compare	  to	  blood.	  
	  
ALDH+	  cells	  are	  reduced	  in	  colon	  tissue	  of	  UC	  patients	  regardless	  of	  inflammation	  	  
The	  production	  of	  RA	  by	  intestinal	  mononuclear	  phagocytes	  has	  been	  suggested	  to	  regulate	  
Th	   cell	   differentiation	   and	   induce	   intestinal	   homing	   properties	   27,	   28.	   As	   generation	   of	   RA	   involves	  
ALDH	  enzymes,	  we	  measured	  ALDH	  activity	  in	  MQs	  and	  DCs	  from	  the	  intestine	  of	  CD	  and	  UC	  patients	  
(Fig.	  5a).	  ALDH	  activity	  did	  not	  differ	  significantly	  between	  DRhi	  and	  DRint	  MQs	  of	  inflamed	  CD	  patients	  
or	  between	  DRhi	  and	  DRint	  MQs	  of	  inflamed	  UC	  patients	  (compare	  the	  same	  patient	  groups	  in	  Fig.	  5b-­‐
c).	   The	   same	   was	   true	   for	   CD141+	   and	   CD1c+	   DCs	   from	   these	   patient	   groups	   as	   well	   as	   controls	  
(compare	  the	  same	  patient	  groups	  in	  Fig.	  5d-­‐e).	  However,	  in	  controls,	  ALDH	  activity	  was	  lower	  in	  DRint	  
MQs	   compared	   to	   DRhi	  MQs	   (median	  %	   (range),	   25%	   (21-­‐49)	   vs.	   56%	   (45-­‐69),	   p=0.0003;	   compare	  
control	   colon	   in	  Fig.	  5b-­‐c).	   In	  general,	  MQ	  and	  DC	  subsets	   from	  the	   ileum	  or	   colon	  of	   inflamed	  CD	  
patients	  had	  a	  broad	  distribution	  in	  the	  frequency	  of	  ALDH+	  cells	  that	  did	  not	  differ	  significantly	  from	  
controls	   (Fig.	  5b-­‐e).	   In	   contrast,	  ALDH	  activity	   in	  DCs	  and	  MQs	   from	   inflamed	  colon	  of	  UC	  patients	  
was	   tightly	   clustered	  and	  all	   four	   subsets	   analyzed	  had	  a	   significantly	   reduced	   frequency	  of	  ALDH+	  
cells	  relative	  to	  control	  colon	  (Fig.	  5b-­‐e).	  Similar	  results	  were	  found	  for	  CD103+	  DCs	  (Supplementary	  
Fig.	   S6a-­‐b).	   This	   suggests	   that,	   relative	   to	   controls,	   the	   frequency	   of	   ALDH+	   myeloid	   cells	   from	  
inflamed	  UC	   colon	  was	   reduced	  while	   ALDH+	  myeloid	   cells	   from	   CD	   colon	   or	   ileum	  was	   similar	   to	  
controls.	  	  
The	  data	  raised	  the	  possibility	  that	   inflamed	  UC	  colon	  reduces	  the	  frequency	  of	  ALDH+	  cells	  
compared	  to	  control	  colon.	  To	  address	  this,	  we	  assessed	  the	  frequency	  of	  ALDH+	  cells	  among	  myeloid	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cells	  from	  UC	  patients	  in	  remission	  and	  in	  non-­‐inflamed	  and	  inflamed	  regions	  of	  the	  intestine	  of	  the	  
same	  UC	   patient	  with	   active	   disease.	   This	   revealed	   that	   DCs,	   but	   not	  MQs,	   showed	   low	   Aldefluor	  
activity	  at	  remission	  compared	  to	  controls	  (Fig.	  5b-­‐e,	  right	  panels).	  Also,	  a	  similar	  frequency	  of	  ALDH+	  
MQs	   and	   DCs	   were	   detected	   in	   non-­‐inflamed	   tissue	   and	   inflamed	   tissue	   of	   patients	   with	   active	  
disease	   (Fig.	   5f).	   Quantitative	   RT-­‐PCR	   of	   sorted	   MQs	   and	   CD141+	   and	   CD1c+	   DCs	   showed	   similar	  
ALDH1A1	   expression	   in	   the	   same	   cell	   type	   among	   the	   different	   patient	   groups	   (Fig.	   5g).	   However,	  
ALDH1A2	  expression	  was	   increased	   in	  all	   three	  cell	   types	  only	   in	   inflamed	  CD	  (Figure	  5g).	  Together	  
the	  data	  suggest	  that	  the	  frequency	  of	  ALDH+	  cells	  in	  the	  colon	  of	  UC	  patients	  with	  active	  disease	  is	  
low	   regardless	   of	   whether	   the	   tissue	   is	   inflamed	   nor	   not.	   It	   also	   shows	   that	   ALDH	   activity	   is	   low	  
among	  DCs	  and	  DRhi	  MQs	  in	  UC	  at	  any	  disease	  stage	  while	  a	  restoration	  of	  ALDH	  activity	  in	  DRint	  MQs	  
is	  apparent	  at	  remission	  	  
	  
Reduced	  ALDH+	  cell	  frequency	  is	  inherent	  to	  the	  colonic	  mucosa	  of	  UC	  patients	  
The	   ALDH	   data	   raise	   the	   possibility	   that	   the	   UC	   colon	   influences	   the	   frequency	   of	   ALDH-­‐
producing	  myeloid	  cells.	  In	  addition,	  ALDH+	  CD45-­‐	  (stromal)	  cells	  did	  not	  compensate	  for	  reduced	  RA	  
in	  UC	  patients	  (Supplementary	  Fig.	  S6c).	  We	  next	  analyzed	  ALDH+	  cells	  among	  blood	  precursors	  (Fig.	  
6a-­‐b).	   The	   data	   revealed	   a	   high	   frequency	   of	   ALDH+	   cells	   among	   classical	   and	   intermediate	  
monocytes,	  as	  well	  as	  among	  circulating	  CD141+	  and	  CD1c+	  DCs,	  in	  UC	  patients	  in	  remission	  and	  with	  
active	   disease	   that	   was	   similar	   to	   healthy	   donors	   (Fig.	   6c).	   ALDH	   activity	   was	   associated	  
predominantly	  with	  ALDH1A1	   expression	   that	  was	   independent	   of	   disease	   or	   disease	   activity	   (Fig.	  
6d).	  Thus,	  the	  low	  frequency	  of	  ALDH-­‐producing	  myeloid	  cells	  in	  the	  colon	  of	  UC	  patients	  in	  remission	  
or	  with	  active	  disease	   is	  not	   reflected	   in	  circulating	  precursors.	  Together	   the	  data	  suggest	   that	   the	  
colon	  environment	  in	  UC	  patients	  reduces	  ALDH	  expression	  of	  mononuclear	  phagocytes.	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DISCUSSION	  
Using	  extensive	  clinical	  material	  encompassing	  Crohn’s	  ileitis,	  Crohn’s	  colitis	  and	  UC,	  as	  well	  
as	  MLNs	  draining	  these	  tissues,	  we	  characterized	  the	  dynamics	  of	  MQ	  and	  DC	  populations,	  including	  
their	  ability	  to	  produce	  RA,	  in	  health	  versus	  IBD.	  Our	  data	  show	  that	  CD	  and	  UC	  patients	  display	  the	  
same	   myeloid	   cell	   imbalance	   in	   inflamed	   intestinal	   mucosa,	   comparisons	   which	   have	   not	   been	  
directly	  made	  before.	  First,	   inflammation	   is	  characterized	  by	   increased	  CD14+	  MQs	   in	   the	   intestinal	  
lamina	  propria.	  These	  cells	  are	  CD64hi,	  consistent	  with	  their	  identity	  as	  MQs	  3,	  6,	  30.	  This	  increase	  was	  
accounted	  for	  by	  CD14+DRint	  cells,	  while	  CD14+DRhi	  cells	  were	  unchanged	  in	  inflammation.	  This	  is	  also	  
consistent	  with	   studies	   in	   Crohn’s	   patients	   showing	   an	   influx	   of	   CD14hi	   cells	   in	   inflamed	   intestinal	  
mucosa	  that	  have	  features	  of	  less	  mature	  mononuclear	  cells	  2,	  3,	  10-­‐12.	  Second,	  we	  studied	  CD141	  and	  
CD1c	  DCs,	  which	  have	  been	  characterized	  in	  several	  healthy	  human	  tissues	  14,	  21,	  24,	  31,	  32	  but	  not	  in	  IBD.	  
We	  found	  that	  the	  number	  of	  CD141+	  and	  CD1c+	  is	  similar	  in	  inflamed	  lamina	  propria	  of	  IBD	  patients	  
and	  controls.	  	  
Expression	  of	  CD103,	  the	  alpha	  chain	  of	  the	  integrin	  αEβ7	  integrin,	  has	  been	  used	  to	  identify	  
a	   population	   of	   DCs	   in	   mouse	   small	   intestine	   with	   a	   role	   in	   homeostasis	   1,	   29,	   33.	   CD103	   is	   not,	  
however,	  a	  subset-­‐specific	  DC	  marker	  as	   it	   is	  expressed	  to	  varying	  degrees	  on	  both	   IRF8/Id2/Batf3-­‐	  
and	   IRF4-­‐dependent	   DCs	   20-­‐22,	   34.	   Notably,	   we	   observed	   a	   marked	   reduction	   in	   the	   frequency	   of	  
CD103-­‐expressing	   DCs	   in	   the	   setting	   of	   intestinal	   inflammation.	   This	   was	   apparent	   among	   both	  
CD141+	  and	  CD1c+	  DCs	  and	  the	  so	  far	  undefined	  CD141-­‐CD1c-­‐	  DCs.	  It	  might	  be	  argued	  that	  although	  
significant,	  the	  differences	  in	  the	  numbers	  of	  CD103-­‐expressing	  cells	  during	  inflammation	  vs.	  health	  
are	   small	   relative	   to	   the	   total	   cell	   count.	  However,	   the	  potency	  of	  DCs	   in	   controlling	   inflammation	  
and	  tolerance	  is	  high	  and	  small	  numbers	  of	  DCs	  can	  have	  a	  potent	  influence	  on	  the	  ensuing	  response	  
in	  the	  tissue.	  Inflammation-­‐induced	  death	  of	  these	  cells,	  their	  migration	  from	  the	  lamina	  propria	  or	  
negative	   impact	   of	   the	   inflammatory	   environment	   on	   CD103	   expression	   may	   underlie	   reduced	  
CD103+	  DCs	  during	  inflammation.	  The	  mechanisms	  regulating	  CD103	  expression	  on	  DCs	  subsequent	  
to	   their	   localization	   in	   the	   intestine	   is	  unknown.	  However,	  CD103	  expression	  on	   intestinal	  T	  cells	   is	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dependent	   on	   TGFβ 35.	   This	   raises	   the	   possibility	   that	   the	   inflammatory	   environment	   of	   IBD	  
negatively	  impacts	  CD103	  expression	  by	  DCs.	  	  
As	  DCs	  migrate	  from	  the	  intestinal	  lamina	  propria	  to	  MLNs	  to	  activate	  naïve	  T	  cells	  20,	  34,	  we	  
investigated	  DCs	  in	  MLNs	  draining	  inflamed	  intestine.	  Strikingly,	  we	  noted	  a	  marked	  increase	  in	  the	  
number	   of	   DRint	   DCs	   among	   CD14-­‐CD64-­‐	   APCs	   in	   MLNs	   draining	   inflamed	   intestine,	   regardless	   of	  
which	  region	  they	  drained.	  Similar	  to	  intestinal	  tissue,	  CD1c+	  DCs	  in	  MLNs	  draining	  inflamed	  or	  non-­‐
inflamed	   intestine	   were	   the	   major	   DC	   subset.	   However,	   in	   inflamed	   tissue,	   the	   CD1c+	   DCs	   were	  
mainly	  DRint	  DCs	  and	  there	  was	  also	  a	  large	  influx	  of	  CD141-­‐CD1c-­‐	  DCs	  that	  were	  DRint.	  The	  three	  DC	  
subsets	  identified	  by	  CD103	  and	  Sirpα	  in	  healthy	  human	  small	  intestine	  express	  CCR7	  24	  and	  can	  thus	  
potentially	  migrate	   to	  MLNs.	  Which	  MLN	  DC	   subset(s)	   represent	   lamina	   propria-­‐derived	  migratory	  
DCs	  and	  resident	  DCs	  in	  the	  steady	  state	  remains	  to	  be	  determined.	  	  
RA	   can	   potentially	   influence	   intestinal	   homeostasis	   by,	   for	   example,	   influencing	   Th	  
differentiation	  and	  inducing	  intestinal	  homing	  receptors	  on	  T	  cells	  9,	  28,	  29,	  36.	  However,	  little	  is	  known	  
about	  RALDH	  activity	  in	  human	  intestinal	  MQ	  and	  DC	  populations	  including	  how	  this	  is	  influenced	  by	  
IBD	  and	  whether	  it	  differs	  in	  ileal	  CD,	  colonic	  CD	  and	  UC.	  We	  observed	  ALDH	  activity	  in	  each	  of	  the	  
mononuclear	  phagocyte	  populations	  examined	  from	  control	  ileum	  and	  colon.	  This	  is	  consistent	  with	  
recent	  studies	  examining	  DCs	  and	  MQs	  from	  healthy	   ileum,	   jejunum	  and	  colon	  24,	   37	  except	  that	  we	  
observed	  ALDH	  activity	  in	  CD141+	  DCs	  from	  ileum	  whereas	  this	  activity	  was	  not	  found	  in	  CD141+	  DCs	  
from	  jejunum	  24.	  	  
Moreover,	  we	  found	  that	  the	  fraction	  of	  ALDH+	  MQs	  and	  DCs	   in	   inflamed	  ileum	  or	  colon	  of	  
CD	  was	   similar	   to	   controls.	   This	   contrasts	   with	   a	   recent	   study	   showing	   increased	   ALDH	   activity	   in	  
CD103+	  and	  CD103-­‐	  DCs	  and	  CD14+	  MQs	  from	  CD	  patients	  37.	  This	  discrepancy	  could	  be	  due	  to	  how	  
DC	  populations	  were	   identified	   in	  the	  studies.	  For	  example,	  Sanders	  et	  al	  analyzed	  ALDH	  activity	   in	  
DCs	   gated	   based	   on	   the	   presence	   or	   absence	   of	   CD103,	   which	   does	   not	   define	   distinct	   DC	  
populations	   23-­‐25.	   In	  contrast,	  we	  analyzed	  DCs	  based	  on	  CD1c	  and	  CD141,	  which	  define	  distinct	  DC	  
subsets	  23-­‐25.	  Moreover,	  samples	  obtained	  from	  different	  intestinal	  sites,	  different	  patient	  treatment	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regimens	   or	   CD	   complications	   such	   as	   strictures	   and	   fistulae	   could	   contribute	   to	   the	   discrepancy.	  
Indeed,	  there	  tended	  to	  be	  more	  individual-­‐to-­‐individual	  spread	  in	  the	  fraction	  of	  ALDH+	  cells	  among	  
our	  CD	  patients	  whereas	   the	  UC	  patients	  behaved	  more	  homogenously.	  Given	  the	  diversity	  among	  
CD	  patients	  with,	   for	  example,	   respect	   to	  disease	   features	   such	  as	   structures	  or	   fistulae,	   it	  may	  be	  
that	   a	   larger	   group	   of	   CD	   patients	   needs	   to	   be	   examined	   and/or	   their	   complications	   need	   to	   be	  
formally	  considered,	   in	  addition	  to	  the	  use	  of	   identical	  gating	  strategies,	   to	  rectify	   the	  discrepancy.	  
Interestingly,	  we	   found	   that	  mRNA	   levels	  of	  ALDH1A2	  were	  higher	   in	  MQs	  and	  DCs	   from	   inflamed	  
colon	   of	   CD	   patients	   compared	   to	   controls.	   This	   indicates	   that	   inflamed	   CD	   patients	   could	   have	  
higher	  ALDH	  activity	  and	  is	  consistent	  with	  the	  data	  of	  Sanders	  et	  al	  37.	  	  
In	  contrast	  to	  inflamed	  CD	  colon,	  ALDH+	  DCs	  and	  MQs	  were	  reduced	  in	  UC	  colon	  compared	  to	  
controls.	   This	   occurred	   even	   in	   UC	   patients	   in	   remission.	   These	   data,	   combined	   with	   the	   similar	  
fraction	   of	   ALDH+	   blood	  monocytes	   in	   UC	   patients	   in	   remission	   and	   healthy	   donors,	   suggests	   that	  
ALDH	  activity	   is	   influenced	  by	  UC	   intestinal	  mucosa	   irrespective	  of	  disease	  activity.	  Consistent	  with	  
Sanders	  et	  al.,	  who	   showed	   that	   circulating	  bulk	  CD14+	  monocytes	  express	  mainly	  ALDH1A1	   37,	  we	  
found	   that	   classical	  and	   intermediate,	  but	  not	  non-­‐classical	  monocytes,	  express	  ALDH1A1	  but	   little	  
ALDH1A2.	  Interestingly,	  a	  large	  fraction	  of	  circulating	  CD141+	  and	  CD1c+	  DCs	  expressed	  ALDH,	  both	  in	  
UC	  and	  controls,	  despite	  low	  ALDH1A1	  expression.	  Enhanced	  efficiency	  of	  the	  oxidation	  of	  retinol	  to	  
retinal	   by	   alcohol	   dehydrogenase	   family	   members	   and/or	   conversion	   of	   retinal	   to	   RA	   by	   RALDH	  
enzymes,	   perhaps	   including	   ALDH1A3	   and	   ALDH2,	   in	   these	   circulating	   DCs	   could	   underlie	   this	  
observation	   28,	   38.	  Whether	   circulating	  CD141+	   and	  CD1c+	  DCs	  migrate	   into	   the	   intestinal	  mucosa	   is	  
unclear	  but	  transcriptional	  profiling	  studies	  support	  this	  possibility	  24	  .	  	  	  
The	   low	  ALDH	  activity	   in	   intestinal	   tissue	  of	  UC	  patients,	  despite	   the	  presence	  of	  ALDH1A1	  
and	  ALDH1A2	  mRNA,	  could	  be	  caused	  by	   translational	  control,	   lack	  of	   factors	   required	  to	  maintain	  
enzyme	  activity	  or	  production	  of	  negative	  regulators.	  The	  microbiota	  composition	  in	  Crohn’s	  disease	  
and	  UC	  differ	  39,	  40,	  and	  the	  microbiota	  can	  influence	  metabolism	  in	  the	  host	  intestine	  41.	  Microbiota-­‐
induced	  alterations	  in	  local	  metabolites	  could,	  in	  turn,	  differentially	  influence	  ALDH	  enzyme	  stability,	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translation	  or	  activity.	  For	  example,	  NAD+	   levels	  are	   influenced	  by	   the	  microbiota	   42,	  and	  NAD+	   is	  a	  
required	  co-­‐factor	  for	  aldehyde	  dehydrogenases	  and	  is	  rate	  limiting,	  along	  with	  Mg2+,	  in	  the	  oxidation	  
of	   retinol	   to	   retinoic	   acid	   43,	   44.	   Thus,	   disease-­‐associated	   microbiota	   could	   influence	   ALDH	   activity	  
despite	   the	   presence	   of	   ALDH1A1	   and	   ALDH1A2	   mRNA.	   For	   negative	   regulation,	   in	   a	   study	  
concerning	   cancer,	   niclosamide	   treatment	   reduced	   Wnt/β-­‐catenin	   signaling	   45.	   This	   resulted	   in	  
increased	  ALDH1A1	   expression	   and	   highlights	   the	   link	   between	  Wnt/β-­‐catenin	   signaling	   and	  ALDH	  
expression.	   Interestingly,	  Wnt/β-­‐catenin	   signaling	   is	   induced	   in	   UC	   but	   not	   Crohn's	   disease	   46	   and	  
many	  Wnt	   ligands	  are	  even	  upregulated	   in	   the	  mucosa	  of	  UC	  patients	   in	   remission	   47.	  Mechanisms	  
regulating	   the	  expression	  and	   function	  of	  enzymes	   involved	   in	   the	  oxidation	  of	   retinol	   in	  MQs	  and	  
DCs	  in	  UC	  patients,	  both	  in	  the	  intestine	  and	  at	  other	  mucosal	  surfaces,	  warrant	  further	  investigation.	  
Could	  reduced	  ALDH	  activity	  in	  the	  lamina	  propria	  affect	  disease	  progression?	  In	  both	  human	  
biopsies	  and	  mice,	  addition	  of	  RA	  activates	  the	  RARα	  receptor	  and	  inhibits	   inflammatory	  responses	  
and	  increases	  FoxP3+	  T	  cells	  even	  without	  lymph	  node	  involvement	  28,	  36,	  48.	  Also,	  all	  trans	  RA	  induces	  
suppressive	  functions	  of	  human	  nTregs	  49.	  Thus,	  local	  regulatory	  failure	  by	  a	  lack	  of	  RA	  may	  help	  drive	  
the	  disease.	  However,	  studies	  in	  mice	  suggesting	  that	  RA	  can	  also	  enhance	  inflammation	  underscore	  
the	   complex	   effects	   of	   RA	   28.	   Despite	   the	   complex	   immunomodulatory	   properties	   of	   RA,	   it	   is	  
successfully	   being	   used	   as	   therapy	   against	   psoriasis	   and	   acne	   and	   may	   be	   involved	   in	   gastric	  
homeostasis	  50-­‐52.	  RA	  modulation	  is	  unlikely	  to	  interfere	  with	  active	  inflammation	  in	  UC,	  but	  may	  be	  
investigated	  as	  a	  supplement	  during	  remission	  to	  reduce	  the	  risk	  of	  relapse.	  	  	  
In	   summary,	   we	   reveal	   a	   myeloid	   cell	   imbalance	   that	   is	   an	   inflammatory	   signature	   in	   the	  
intestinal	   lamina	  propria	  and	  MLNs	  that	   is	  common	  to	  CD	  and	  UC.	  Moreover,	   it	   is	  similar	  along	  the	  
colon	   and	   terminal	   ileum.	   Our	   data	   also	   suggest	   that	   the	   intestinal	   environment	   of	   UC	   influences	  
ALDH	  activity	  of	  mononuclear	  phagocytes,	  irrespective	  of	  the	  inflammatory	  status	  of	  the	  patient	  per	  
se.	  Down	  regulation	  of	  the	  retinoic	  acid	  system	  seems	  to	  be	  a	  feature	  of	  UC,	  active	  as	  well	  as	  inactive,	  
and	  therapeutic	  normalization	  of	  this	  phenomenon	  may	  represent	  a	  new	  treatment	  target	  in	  UC.	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MATERIALS	  AND	  METHODS	  
Patients	  and	  specimens	  
UC	   patients,	   CD	   patients	   and	   non-­‐inflamed	   controls	   (Table	   1)	  were	   recruited	   during	   2010-­‐
2015	   at	   the	   Endoscopy	   unit,	   Sahlgrenska	   University	   Hospital,	   Gothenburg,	   Sweden,	   at	   the	  
Department	  of	  Surgery,	  Östra	  Hospital,	  Gothenburg,	  Sweden,	  at	   the	  Department	  of	  Surgery,	  Skåne	  
University	  Hospital,	   SUS	  Malmö,	   Sweden	   and	   at	  Department	   of	  Hepatology	   and	  Gastroenterology,	  
Aarhus	   University	   Hospital,	   Aarhus,	   Denmark.	   All	   participants	   gave	   informed	  written	   consent.	   The	  
study	  was	  approved	  by	  the	  Regional	  Ethical	  Review	  Board	   in	  Gothenburg	  (permits	  040-­‐08	  and	  085-­‐
11),	  the	  Regional	  Ethical	  Board	  in	  Lund	  (permit	  463-­‐06)	  and	  the	  Local	  Scientific	  Ethical	  committee	  in	  
Denmark	  (permits	  M-­‐20100216	  and	  M-­‐20110240).	  
Tissue	   biopsies	   were	   acquired	   at	   routine	   colonoscopy.	   Inflammation	   was	   assessed	  
macroscopically	  by	   the	  examining	  gastroenterologist	   and	  microscopically	  by	  a	  pathologist.	  Biopsies	  
from	   patients	   without	   inflammation	   undergoing	   colonoscopy	   for	   other	   indications	   (polyps,	   weight	  
loss)	   were	   non-­‐inflamed	   control	   tissue	   (termed	   controls).	   Tissue	   and	   MLNs	   from	   surgery	   were	  
acquired	   from	   UC	   and	   CD	   patients	   undergoing	   colectomy	   or	   ileectomy.	   Non-­‐inflamed	   tissue	   and	  
MLNs	   from	   surgery	   were	   from	   patients	   undergoing	   bladder	   reconstruction	   by	   cystectomy	   (also	  
termed	   controls).	   Blood	  was	   from	   healthy	   donors,	   UC	   patients	   in	   remission	   and	   UC	   patients	   with	  
active	  disease.	  
	  
Blood	  and	  intestinal	  samples	  
Peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  were	  isolated	  from	  heparinized	  venous	  blood	  by	  
density-­‐gradient	   centrifugation	   on	   Ficoll-­‐Paque	   (GE	   Healthcare,	   Sweden).	   Biopsies	   and	   surgical	  
samples	  were	  collected	  in	  PBS	  and	  put	  on	  ice.	  Surgical	  samples	  were	  stripped	  of	  muscle	  and	  fat	  and	  
cut	  into	  small	  pieces.	  Epithelial	  cells	  were	  removed	  by	  incubating	  for	  15	  min	  at	  37°C	  with	  HBSS-­‐EDTA	  
(HBSS	  containing	  2%	  FCS,	  1.5	  mM	  Hepes	  and	  2	  mM	  EDTA)	  three	  times	  followed	  by	  a	  wash	  in	  RPMI	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1640	   containing	   10%	   FCS	   and	   1.5	   mM	   Hepes.	   Lamina	   propria	   mononuclear	   cells	   (LPMCs)	   were	  
prepared	  by	  a	  45-­‐60	  minute	  incubation	  at	  37°C	  with	  25	  CDU/ml	  collagenase	  type	  VIII	  (Sigma-­‐Aldrich)	  
or	   40	   CDU/ml	   collagenase	   D	   (Roche	   Diagnostics)	   and	   60	   Kunitz	   units/ml	   DNase	   I	   (Sigma-­‐Aldrich)	  
diluted	   in	   RPMI	   1640	  with	   10%	   FCS,	   1.5	  mM	  Hepes	   and	   2	  mM	  CaCl2.	   Following	   digestion,	   surgical	  
samples	   were	   further	   dissociated	   using	   a	   GentleMACS	   (Miltenyi	   Biotec,	   Germany).	   Supernatants	  
were	  collected	  by	  filtration	  through	  a	  nylon	  mesh	  and	  analyzed	  by	  flow	  cytometry.	  Cell	  suspensions	  
from	  MLNs	  were	  obtained	  by	   cutting	   it	   into	  pieces	  and	  performing	   collagenase	  digestion	  as	  above	  
but	  for	  30	  min.	  	  	  
	  
Flow	  cytometry	  
Cells	   were	  washed	   twice	   in	   HBSS	   containing	   2%	   FCS,	   5	  mM	   EDTA	   and	   20	  mM	  HEPES	   and	  
stained	   in	   the	   same	   buffer	   for	   30	   min	   at	   4°C	   in	   the	   dark.	   	   7-­‐Aminoactinomycin	   D	   (7AAD,	   Sigma-­‐
Aldrich)	  or	  Live/Dead	  Fixable	  Aqua	  Dead	  Cell	  Stain	  Kit	  (Gibco	  Life	  Technologies)	  were	  used	  to	  exclude	  
non-­‐viable	  cells.	  Antibodies	  used	  were:	  anti-­‐HLADR-­‐Alexa700/APC-­‐Cy7,	  anti-­‐CD3-­‐PE-­‐CF594/FITC,	  anti-­‐
CD19-­‐PE-­‐CF594/FITC,	   anti-­‐CD56-­‐PE-­‐CF594,	   anti-­‐CD11c-­‐Pacific	   Blue/PeCy7,	   anti-­‐CD14-­‐PeCy7/FITC,	  
anti-­‐CD103-­‐PE/APC,	   anti-­‐CD141-­‐PE,	   anti-­‐CD1c-­‐PerCP-­‐Cy5.5,	   anti-­‐CD45-­‐APCH7,	   anti-­‐CD16-­‐APC,	   anti-­‐
CD64/APC,	   anti-­‐CD13/APC,	   anti-­‐CD33/APC,	   anti-­‐CD209/APC	   and	   anti-­‐Sirpα/PeCy7.	   Antibodies	  were	  
from	  BD	  Biosciences	  (San	  Jose,	  CA)	  except	  anti-­‐CD103	  (eBioscience),	  anti-­‐HLA-­‐DR	  (BioLegend),	  anti-­‐
CD1c	  (BioLegend)	  and	  anti-­‐CD141	  (Miltenyi).	  Samples	  were	  collected	  with	  a	  LSRII-­‐	  or	  FACSCAnto	  (BD	  
Biosciences)	  using	  DIVA	   software	   (BD	  Biosciences)	   and	  analyzed	  using	   FlowJo	   software	   (Tree	   Star).	  
Lineage	   cocktail	  was	   anti-­‐(CD3/CD19/CD56).	   Isotype	   controls	  were	   used	   for	   anti-­‐CD14-­‐PeCy7/FITC,	  
anti-­‐CD103-­‐PE/APC,	   anti-­‐CD141-­‐PE,	   anti-­‐CD1c-­‐PerCP-­‐Cy5.5,	   anti-­‐CD64/APC,	   anti-­‐CD13/APC,	   anti-­‐
CD33/APC,	  anti-­‐CD209/APC	  and	  anti-­‐Sirpα/PeCy7.	  	  
Classical	   (Lin-­‐CD14+CD16-­‐),	   intermediate	   (Lin-­‐CD14+CD16+)	   and	   non-­‐classical	   (Lin-­‐
CD14lowCD16+)	   monocytes	   as	   well	   as	   CD141+	   (Lin-­‐CD14-­‐CD16-­‐HLADR+CD141+)	   and	   CD1c+	   (Lin-­‐CD14-­‐
CD16-­‐HLADR+CD1c+)	   cells	   were	   sorted	   from	   peripheral	   blood.	   For	   Fig.	   5g,	   total	   CD14+	   MQs	   were	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analyzed	  (called	  DRhi/DRint	  MQs	  in	  Fig.	  5g)	  since	  DRint	  MQs	  were	  too	  few	  from	  control	  tissue	  and	  DRhi	  
MQs	  were	  too	  few	  from	  inflamed	  tissue.	  Total	  CD14+	  MQs,	  	  CD141+	  DCs	  and	  CD1c+	  DCs	  were	  sorted	  
from	   intestinal	   tissue	   from	  the	   indicated	  patient	  groups.	  Samples	  were	  sorted	  using	  a	  FACS	  Aria	   III	  
(BD	  Biosciences).	  Purity	  was	  >98%.	  
	  
ALDH	  activity	  
ALDH	   activity	   was	   evaluated	   using	   the	   Aldefluor	   assay	   (Stemcell	   Technologies,	   France)	  
according	   to	   the	   manufacturer’s	   protocol	   with	   some	   modifications.	   Briefly,	   7x106	   cells	   were	  
resuspended	   in	   0.5	  ml	   assay	  buffer	   containing	  5	  µl	   Aldefluor	   reagent	  without	  or	  with	  10	  µl	   of	   the	  
ALDH	  inhibitor	  DEAB	  (15	  µM).	  Samples	  were	   incubated	  at	  37°C	  for	  45	  min	   in	  the	  dark.	   	  ALDH+	  cells	  
were	   identified	   as	   cells	   with	   brighter	   fluorescent	   intensity	   than	   a	   DEAB-­‐inhibited	   sample	   run	   in	  
parallel.	  	  
	  
RNA	  isolation	  and	  qPCR	  
RNA	  was	   extracted	   using	  NucleoSpin	   RNA	   kit	   (Macherey-­‐Nagel	   GmbH,	   Belgium)	   and	   cDNA	  
was	  produced	  using	  Quantitect	  Reverse	  Transcription	  Kit	  (Qiagen).	  Quantitative	  real-­‐time	  PCR	  (qPCR)	  
was	   performed	   using	   TaqMan	   Universal	   PCR	   Master	   Mix	   (Applied	   Biosystems).	   Expression	   of	  
ALDH1A1	   (Hs00946916_m1),	   ALDH1A2	   (Hs00180254_m1),	   GAPDH	   (Hs03929097_g1)	   and	   HPRT	  
(Hs01003267_m1)	   (all	   from	   Applied	   Biosystems)	   were	   quantitated	   using	   the	   7500	   Real	   Time	   PCR	  
system	   (Applied	   Biosystems).	   Standard	   conditions	   for	   relative	   gene	   expression	   analysis	   as	  
recommended	   by	   the	  manufacturer	  were	   applied.	   Expression	   data	  was	   normalized	   to	  GAPDH	   and	  
HPRT	  using	  the	  2-­‐ΔCt	  method.	  	  	  	  	  
	  
Statistics	  	  
Statistical	  evaluations	  were	  performed	  using	  GraphPad	  Prism	  6.0	  (GraphPad	  Software,	  USA).	  
Wilcoxon	  signed	  rank	  test	  was	  used	  to	  evaluate	  differences	  between	  paired	  samples,	  Mann	  Whitney	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U	  test	  was	  performed	  to	  evaluate	  differences	  between	  two	  groups	  and	  Kruskal-­‐Wallis	  test	  followed	  
by	  Dunn’s	  multiple	  comparison	  was	  used	  for	  comparison	  between	  three	  or	  more	  groups.	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Figure	  1.	  DRint	  MQs	  infiltrate	  inflamed	  intestinal	  mucosa	  in	  CD	  and	  UC.	  (a)	  Gating	  strategy	  used	  to	  
select	   live,	   Lin-­‐HLADR+CD14+	   cells.	   (b)	   Lin-­‐HLADR+CD14+	   were	   further	   divided	   into	   DRhi	   and	   DRint	  
populations.	   (c)	   The	   number	   of	  DRhi	  MQs	   and	   (e)	  DRint	  MQs	   among	   105	   LPMCs	   from	   the	   indicated	  
tissue	  is	  shown.	  Control	  tissue	  for	  CD	  and	  UC	  were	  from	  ascending	  and	  sigmoid	  colon,	  respectively.	  
Horizontal	  lines	  indicate	  the	  median.	  (d)	  The	  number	  of	  DRhi	  MQs	  and	  (f)	  DRint	  MQs	  among	  105	  LPMCs	  
from	  non-­‐inflamed	  and	  inflamed	  areas	  of	  the	  same	  patient	  is	  shown.	  ns	  =	  non-­‐significant.	  
	  
Figure	  2.	  HLADR	  expression	  on	  intestinal	  DRint	  MQs	  resembles	  CD14+	  blood	  monocytes.	  (a)	  Gating	  
strategy	   used	   to	   select	   live,	   Lin-­‐CD14+	   blood	   cells	   (monocytes).	   (b)	   Median	   fluorescence	   intensity	  
(MFI)	   of	   HLADR	   on	   CD14+	   monocytes	   and	   intestinal	   DRint	   and	   DRhi	   MQs.	   Paired	   blood	   and	   tissue	  
samples	  were	  obtained	  from	  five	  UC	  patients	  in	  remission.	  Horizontal	  lines	  indicate	  the	  median.	  	  
	  
Figure	   3.	   Lamina	   propria	   CD141+CD103+and	   CD1c+CD103+	   DCs	   decrease	   during	   inflammation.	   (a)	  
Gating	  strategy	  for	  DCs.	  The	  CD14-­‐	  population	  in	  Figure	  1a	  was	  further	  gated	  as	  CD11c+	  (left).	  These	  
cells	   were	   then	   divided	   into	   CD141+	   and	   CD1c+	   DC	   populations	   (middle)	   and	   further	   gated	   into	  
CD141+CD103+	   and	   CD1c+CD103+	   DCs	   (right).	   Isotype	   control	   for	   CD103	   (total	   DC	   population)	   and	  
CD103	   control	   staining	   of	   DRhi	   MQs	   are	   shown.	   The	   number	   of	   CD141+CD103+DCs	   (b)	   and	  
CD1c+CD103+DCs	  (d)	  among	  105	   live	  LPMCs	  from	  the	  indicated	  tissue	  is	  shown.	  Control	  samples	  are	  
as	  in	  Fig.	  1.	  Horizontal	  lines	  indicate	  the	  median.	  The	  frequency	  of	  CD103+	  cells	  among	  CD141+	  DCs	  (c)	  
and	  CD1c+	  DCs	  (e)	  from	  non-­‐inflamed	  and	  inflamed	  areas	  of	  the	  same	  patient	  is	  shown.	  	  
	  
Figure	   4.	   Increased	   DRint	   DCs	   characterize	   MLNs	   draining	   inflamed	   ileum	   and	   colon.	   (a)	   Gating	  
strategy	   to	   identify	  MLN	   DCs.	   Live,	   lin-­‐CD45+HLADR+CD14-­‐	   cells	   were	   gated	   for	   CD11c	   and	   further	  
divided	  into	  DRhi	  and	  DRint	  DCs.	  (b)	  The	  DRhi/	  DRint	  DC	  ratio	  in	  the	  MLN	  draining	  the	  indicated	  tissue	  is	  
shown.	  Horizontal	   lines	  indicate	  the	  median.	  (c)	  Schematic	  showing	  where	  the	  colon-­‐draining	  MLNs	  
 25 
used	  to	  generate	  the	  DRhi/	  DRint	  DC	  ratio	   in	   (b)	  were	  taken.	  Each	  color	   in	   (c)	  correlates	  to	  the	  DRhi/	  
DRint	  DC	  ratio	  of	  the	  same	  color	  (individual)	  in	  (b).	  (d)	  DRhi	  DCs	  (blue)	  and	  DRint	  DCs	  (red)	  were	  further	  
gated	   into	  CD141+,	  CD1c+	  and	  CD141-­‐CD1c-­‐	  DCs	  and	  displayed	  as	  pie	  charts	   in	  (e).	   (f)	  MFI	  of	  HLADR	  
expression	  on	  lamina	  propria	  CD141+,	  CD1c+	  and	  CD141-­‐CD1c-­‐	  DCs	  from	  non-­‐inflamed	  and	  inflamed	  
colon	  tissue	  of	  patients	  from	  whom	  MLNs	  were	  also	  obtained	  (a	  subset	  of	  the	  patients	  shown	  in	  4a-­‐e;	  
CD	  ileum	  n=2,	  CD	  colon	  n=2	  and	  UC	  colon	  n=2).	  Open	  triangles	  are	  ileal	  CD;	  open	  circles	  are	  colonic	  
CD	  and	  closed	  circles	  are	  UC.	  
	  
Figure	   5.	   Low	   frequency	   of	   ALDH+	   DCs	   and	  MQs	   characterizes	   inflamed	   UC	   lamina	   propria	   .	   (a)	  
Histograms	  of	  ALDH+	  cells	  among	  the	  indicated	  populations	  from	  the	  colon	  of	  an	  inflamed	  CD	  colitis	  
patient.	   Cells	  were	   incubated	  with	   ALDEFLUOR	   in	   the	   absence	   (filled)	   or	   presence	   (dotted	   line)	   of	  
DEAB	  inhibitor.	  The	  percent	  Aldeflour+	  cells	  is	  shown	  above	  the	  horizontal	  line	  indicating	  the	  positive	  
gate.	  The	  frequency	  of	  ALDH+	  cells	  among	  DRhi	  MQs	  (b),	  DRint	  MQs	  (c),	  CD141+	  DCs	  (d)	  and	  CD1c+	  DCs	  
(e)	   in	   inflamed	  tissue	  (CD	  and	  UC)	  and	  in	  remission	  (UC)	  compared	  to	  controls	   is	  shown.	  Horizontal	  
lines	  indicate	  the	  median.	  	  (F)	  The	  frequency	  of	  ALDH+	  cells	  among	  DRhi	  MQs,	  DRint	  MQs,	  CD141+	  DCs	  
and	   CD1c+	   DCs	   from	   non-­‐inflamed	   and	   inflamed	   areas	   of	   the	   same	   patient	   is	   shown.	   (g)	   RT-­‐PCR	  
analysis	  of	  ALDH1A1	  and	  ALDH1A2	  expression	  relative	  to	  HPRT	  by	  total	  CD14+	  MQs	  (called	  DRhi/DRint	  
MQs	   in	   the	   figure),	   CD141+	  DCs	   and	   CD1c+	  DCs	   purified	   from	   intestinal	   tissue	   by	   sorting	   using	   the	  
gates	   in	   Figure	   1a	   and	  3a	   is	   shown	   (control	   n=4,	  UC	  n=4	   and	  CD	  n=4).	   Bars	   show	   the	  median	   and	  
range.	   Statistical	   significance	   is	   indicated	   with	   the	   p-­‐value	   and	   all	   other	   comparisons	   were	   non-­‐
significant.	  
	  
Figure	  6.	  Similar	  frequency	  of	  circulating	  ALDH+	  cells	  in	  UC	  patients	  and	  healthy	  donors.	  (a-­‐b)	  Gating	  
strategy	  showing	  PBMCs	  of	  a	  healthy	  donor.	  Live,	  Lin-­‐HLADR+CD45+	  cells	  were	  further	  gated	  into	  (a)	  
non-­‐classical	   (CD14lowCD16+),	   intermediate	   (CD14+CD16+)	  and	  classical	   (CD14+CD16-­‐)	  monocytes	  and	  
CD14-­‐CD16-­‐	  cells.	  (b)	  The	  double	  negative	  cells	  were	  further	  gated	  into	  CD141+	  and	  CD1c+	  cells.	  ALDH+	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cells	  were	  identified	  as	  in	  Fig.	  5.	  The	  frequency	  of	  ALDH+	  cells	  among	  (c)	  classical,	   intermediate	  and	  
non-­‐classical	  monocytes	   as	   well	   as	   CD141+	   and	   CD1c+	   cells	   from	   the	   blood	   of	   healthy	   donors,	   UC	  
patients	   with	   active	   disease	   and	   UC	   patients	   in	   remission	   is	   shown.	   	   Horizontal	   lines	   indicate	   the	  
median.	  	  (d)	  RT-­‐PCR	  analysis	  of	  ALDH1A1	  and	  ALDH1A2	  expression	  relative	  to	  HPRT	  by	  the	  indicated	  
cell	   populations	   purified	   from	   the	   blood	   of	   healthy	   donors	   (n=5),	   UC	   patients	   with	   active	   disease	  
(n=4)	  and	  UC	  patients	  in	  remission	  (n=3)	  by	  sorting	  using	  the	  gates	  in	  (a-­‐b).	  nd	  =	  not	  detected.	  Bars	  
show	  median	  and	  range.	  All	  comparisons	  were	  non-­‐significant.	  
	  
Supplementary	   Figure	   S1.	   Surface	   marker	   expression	   and	   frequency	   of	   DRhi	   and	   DRint	   MQs.	   (a)	  
LPMCs	   from	  a	   control	  patient	  were	  pregated	  as	   in	   Figure	  1a	   (left)	   and	  gating	   for	  CD14+	   and	  CD14-­‐	  
cells	   compared	   to	   isotype	   control	   is	   shown..	   (b)	   Histograms	   showing	   surface	   expression	   of	   CD64,	  
CD13,	   CD33,	   CD209	   and	   Sirpα	   on	   DRhi	   and	   DRint	   MQs	   from	   control	   colon	   (open	   histogram)	   and	  
inflamed	  Crohn’s	  colon	  (filled	  histogram)	  is	  shown.	  Isotype	  control	  is	  indicated	  with	  a	  dotted	  line.	  (c-­‐
d)	  The	  frequency	  of	  DRhi	  MQs	  (c)	  and	  DRint	  MQs	  (d)	  among	  LPMCs	  from	  the	  indicated	  tissue	  is	  shown.	  
Control	  tissue	  for	  CD	  and	  UC	  were	  from	  ascending	  and	  sigmoid	  colon,	  respectively.	  Horizontal	   lines	  
indicate	  the	  median.	  ns	  =	  non-­‐significant.	  
	  
Supplementary	  Figure	  S2.	  The	   frequency	  of	  CD141+	  and	  CD1c+	  DCs	  among	   total	   LPMCs	  or	   lamina	  
propria	  DCs	   remains	  constant	  during	   inflammation.	   (a)	  LPMCs	   from	  the	  colon	  of	  a	  control	  patient	  
were	  pregated	  as	  in	  Figure	  3a	  (left)	  and	  further	  gated	  for	  CD141	  or	  CD1c	  as	  shown	  relative	  to	  isotype	  
control.	   The	   frequency	   of	   CD141+	   DCs	   (b)	   and	   CD1c+	   DCs	   (c)	   among	   total	   live	   LPMCs	   and	   the	  
frequency	  of	  CD141+	  DCs	  (d)	  and	  CD1c+	  DCs	  (e)	  among	  lamina	  propria	  DCs	  are	  shown.	  Horizontal	  lines	  
indicate	  the	  median.	  ns	  =	  non-­‐significant.	  
	  
Supplementary	  Figure	  S3.	  The	  frequency	  of	  CD103+	  cells	  among	  CD141-­‐CD1c-­‐	  DCs	  is	  reduced	  during	  
colitis.	  (a)	  Gating	  strategy	  for	  CD103+	  DCs	  among	  CD141-­‐CD1c-­‐	  DCs.	  The	  CD14-­‐	  population	  in	  Figure	  1a	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was	   further	   gated	   as	   CD11c+	   (left)	   and	   then	   into	   CD141-­‐CD1c-­‐	   DCs	   (middle)	   for	   analysis	   of	   CD103	  
(right).	   Isotype	  control	   for	  CD103	  (total	  DC	  population)	  and	  CD103	  control	  staining	  of	  DRhi	  MQs	  are	  
shown.	   (b)	   The	   frequencies	   of	   CD103+	   cells	   among	   CD141-­‐CD1c-­‐	   DCs	   is	   shown	   for	   the	   indicated	  
tissues.	  Horizontal	  lines	  indicate	  the	  median.	  ns	  =	  non-­‐significant.	  
	  
Supplementary	   Figure	   S4.	   Lamina	   propria	   CD103+	   DCs	   decrease	   during	   inflammation.	   (a)	   Gating	  
strategy	  for	  CD103+	  DCs.	  The	  CD14-­‐	  population	  (top	  left)	  was	  further	  gated	  as	  CD11c+	  cells	  (left)	  that	  
were	  divided	  into	  CD103+	  and	  CD103-­‐	  populations	  (right).	  (b)	  The	  number	  of	  CD103+	  DCs	  among	  105	  
live	  LPMCs	  and	  (c)	  the	  frequency	  of	  CD103+	  DCs	  among	  total	  APCs	  from	  the	  indicated	  tissue	  is	  shown.	  
Control	  samples	  are	  as	  in	  Fig.	  1.	  Horizontal	  lines	  indicate	  the	  median.	  (d)	  The	  frequency	  of	  CD103+DCs	  
from	  non-­‐inflamed	  and	  inflamed	  areas	  of	  the	  same	  patient	  is	  shown.	  	  	  
	  
Supplementary	  Figure	  S5.	  HLADR	  expression	  is	  higher	  on	  CD141+	  and	  CD1c+	  cells	  from	  the	  intestine	  
compared	  to	  the	  blood.	   (a)	  Gating	  strategy	  used	  to	  select	   live,	  Lin-­‐HLADR+	  blood	  cells	   (left)	   further	  
gated	  into	  CD141+	  (top)	  and	  CD1c+	  (bottom)	  cells.	  (b)	  MFI	  of	  HLADR	  on	  CD141+	  and	  CD1c+	  cells	  from	  
the	  blood	  and	  intestinal	  tissue	  of	  the	  same	  patient.	  Paired	  blood	  and	  tissue	  samples	  were	  obtained	  
from	  UC	  patients	  in	  remission.	  	  
	  
Supplementary	   Figure	   S6.	   ALDH	   activity	   in	   intestinal	   CD103+	   DCs	   and	   lamina	   propria	   CD45+	   and	  
CD45-­‐	  cells.	  (a)	  Histogram	  of	  ALDH	  expression	  by	  CD103+	  DCs	  from	  the	  colon	  of	  an	  inflamed	  CD	  colitis	  
patient	   is	   shown.	   Cells	   were	   gated	   as	   in	   Supplementary	   Figure	   S4a.	   Cells	   were	   incubated	   with	  
ALDEFLUOR	   in	   the	   absence	   (filled)	   or	   presence	   (dotted	   line)	   of	   DEAB	   inhibitor.	   The	   percent	   of	  
Aldeflour+	  cells	   is	  shown	  above	  the	  horizontal	   line	  indicating	  the	  positive	  gate.	  (b)	  The	  frequency	  of	  
ALDH+	  cells	  among	  CD103+	  DCs	  in	  inflamed	  CD	  or	  UC	  tissue	  and	  in	  UC	  patients	  in	  remission	  compared	  
to	   controls	   is	   shown.	   (c)	   The	   frequency	  of	  ALDH+	   cells	   among	   and	  CD45+	   and	  CD45-­‐	   LPMCs	   for	  UC	  
patients	  in	  remission	  and	  controls	  is	  shown.	  Horizontal	  lines	  indicate	  the	  median.	  	  	  














